• Insilico Medicine nominated ISM0387, an MTA-cooperative PRMT5 inhibitor, as a preclinical candidate discovered by its UAE team using Pharma.AI.
• Program completed early discovery workflow in UAE in less than 12 months, including hit generation within 30 days.
• Lead optimization finished within 6 months, signaling faster cycle times for AI-driven R&D execution.
• ISM0387 showed improved in vitro activity and selectivity, with enhanced brain penetration.
• Candidate is positioned as a potential glioblastoma treatment; nomination marked Insilico Medicine’s 30th AI-supported preclinical candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260424-12120171), on April 24, 2026, and is solely responsible for the information contained therein.